Typed gene group for breast cancers and application of typed gene group
A breast cancer and gene group technology, applied in biochemical equipment and methods, DNA/RNA fragments, microbial determination/inspection, etc., can solve problems such as uncertain ratio, inability to be accurately confirmed, and inaccurate PAM50 molecular typing
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0025] Embodiment 1, breast cancer genotyping
[0026] This technology divides breast cancer into three subtypes by detecting gene expression: mesenchymal, proliferative, and metabolic.
[0027] According to the gene expression data of 251 breast cancer patients (GSE3494, Angfei HG-U133A detection platform), we used cluster analysis to obtain three subtypes of breast cancer patients: mesenchymal type, proliferative type and metabolic type. Comparing the gene expression of one of the types with the other two, we get the genetic fingerprints of the three types. Taking the mesenchymal type as an example, the expression value of the genes of this fingerprint in the mesenchymal type is significantly higher than that in the other two subtypes (expression fold FC>1.5, p<0.05). Table 1 lists typical genetic fingerprints (60 genes) of three breast cancer subtypes.
[0028] Table 1 The 60 genes of breast cancer typing gene group
[0029]
[0030]
[0031]
[0032]
[0033...
Embodiment 2
[0058] Example 2. Therapeutic Effects of Drugs on Three Subtypes of Breast Cancer
[0059] 1. Patients with mesenchymal breast cancer significantly benefited from tamoxifen
[0060] The gene expression data and clinical data of 189 breast cancer patients were downloaded from the GEO database (GSE2990), and 2 patients had no clinical data. Patient data were obtained from John Radcliffe Hospital, Oxford, UK, and Uppsala University Hospital, Uppsala, Sweden. like figure 1 As shown, in the case of 125 breast cancer patients without drug treatment, there was no significant difference in the recurrence-free survival rate of the three subtypes of breast cancer patients, including 54 patients with mesenchymal type and 38 patients with proliferative type. The number of metabolic patients was 33.
[0061] like figure 2 As shown, the number of patients with mesenchymal breast cancer is 17, the number of proliferative patients is 19, and the number of metabolic patients is 26. After ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap